Queen's University
Kingston, Ontario, K7L 3N6, Canada
NCT Number: NCT04630197
This study will implement an e-CBT program for OCD and observe its effects on brain activation levels using functional magnetic resonance imaging (fMRI). It is hypothesized that brain activation levels in the basal ganglia and frontal cortex will decrease following treatment. Individuals with OCD will be offered a 16-week e-CBT program with ERP mirroring in-person CBT content that will be administered through a secure online platform. Efficacy of treatment will be evaluated using clinically validated symptomology questionnaires at baseline, week 8, week 16, and at a 6-month follow-up. Using fMRI at baseline and post-treatment, brain activation levels will be assessed at resting state, and while exposed to anxiety-inducing images (i.e., dirty dishes if cleanliness is an obsession). The effects of treatment on brain activation levels and the correlation between symptom changes and activation levels will be analyzed.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Kingston, Ontario, K7L 3N6, Canada
Study Design:
A non-randomized pilot study design will be employed. Functional magnetic resonance imaging (fMRI) will be conducted at baseline and post-treatment to evaluate activation level changes in the basal ganglia and frontal cortex. Clinically validated symptomology questionnaires will be used to evaluate treatment efficacy. Additionally, qualitative interviews will be conducted to gather personal demographic information as well as information regarding participant experience while using the online psychotherapy clinic. This study has been registered on the ClinicalTrials.Gov Protocol Registration and Results System (NCT04630197). Additionally, ethics approval has been obtained from the Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (HSREB).
Participants:
Participants (n = 10) will be recruited from family medicine and psychiatric clinics at Queen's University and Kingston Health Sciences Centre sites (Hotel Dieu Hospital and Kingston General Hospital) in Kingston, Ontario, Canada. Additionally, local and social media advertisements will be utilized. Participants will be enrolled in the study based on referrals from outpatient clinics, family doctors, as well as self-referrals. Those invited and interested in participating will have the study protocol explained along with an evaluation by a psychiatrist on the research team through a secured video appointment. Participants will be evaluated for a diagnosis of OCD based on the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) [48]. Once a diagnosis of OCD is confirmed and the participant is given written and verbal instructions on how to participate in the online therapy, informed consent will be obtained. Inclusion criteria include the following: between the ages of 18 and 65 years at the start of the study, a diagnosis of OCD according to DSM-5, competence to consent to participate, ability to speak and read English, and consistent and reliable access to the internet. Exclusion criteria include having any metal implants or additional factors deemed not safe to undergo an MRI scan, active psychosis, acute mania, severe alcohol or substance use disorder, and/or active suicidal or homicidal ideation. Additionally, if a participant is receiving another form of psychotherapy, they will be excluded from the study.
e-CBT Protocol: Weekly sessions of e-CBT will be conducted through the Online Psychotherapy Tool (OPTT), a secure, online, cloud-based mental health care delivery platform. These online sessions will consist of approximately 30 slides and interactive therapist videos, with 16 modules in total (1 module per week). The content and format of these online sessions will mirror in-person CBT for OCD. The connection between thoughts, behaviours, emotions, physical reactions, and the environment will be a focus. Moreover, mindfulness, body scanning, self-care, goal setting, thinking errors, the 5-part model, and thought records will be employed as techniques for participants. ERP will be incorporated into the e-CBT program as this is the first-line route of treatment. Slides will highlight different topics each week and include general information, an overview of skills, and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by therapists with personalized feedback provided within 3 days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. After each completion of the e-CBT program, participants will be interviewed to investigate their experience using OPTT and their perception of how the treatment went. Participants can access their therapy sessions from any device with internet access (desktop computer, laptop, cellphone, tablet) and can be run on a variety of internet browsers.
fMRI Protocol: All imaging procedures will occur at the Queen's University MRI Facility in Kingston, Ontario, Canada using a Siemens 3.0 Tesla whole-body MRI scanner with a standard coil. Scans will occur at baseline (pre-treatment), after week 16 (post-treatment, and at a 6-month follow-up. During scanning, participants will lay on the scanning table on their back, with their head resting on a foam pad to reduce movement. Appointments will be 1 hour.
Anatomical reference images will be captured initially. Following this, fMRI scans will occur while participants are shown neutral images and anxiety-inducing images (i.e., dirty dishes if cleanliness is an anxiety-inducing concept for a specific participant). The frontal cortex and basal ganglia will be the focuses of the imaging procedures as we are interested in the activation level changes during neural anxiety processing. These images will be standardized pictures from the International Affective Picture System (IAPS) that will be selected specifically for each patient by members of our research team.
Participants will be shown a total of 40 images (20 neutral, 20 anxiety-inducing; R = 0.5) during the fMRI scans. There will be 4 fMRI runs that occur in the following sequence:
The images will be shown in sets (groups of 5) as opposed to intermingled as we hope this will produce a more sustained emotional state and allow for more distinct readings. The reasoning of the sets being repeated in the middle (back-to-back of the anxiety-inducing images in the example above) is for participants to not become as accustomed to the ordering. Moreover, we will change this ordering for every participant (i.e, The next participant would receive back-to-back sets of the neutral imaging in runs 2 and 3). This is done to counterbalance the imaging sets. Participants will be prompted to imagine themselves in the situations described in the images. The images will appear on a screen and then be reflected into the scanner for participants to view. 0.5% blood oxygen level-dependent (BOLD) signal difference between conditions (p < 10-6) will be considered a detectable change (eff = 0.005).
Anatomical reference images will be captured with the phase encoding direction collected sagitaly from anterior to posterior. These images will be captured with T1-weighted high-resolution magnetization prepared rapid acquisition gradient echo (MPRAGE) images with 1 x 1 x 1 mm3 isotropic voxels. For the stimuli-exposed image acquisitions, T2*-weighted gradient-echo echo-planar imaging (GE-EPI) with 1.5 x 1.5 x 2 mm3 voxels will be used. A flip angle of 90 degrees and a bandwidth of 1500 Hz will be used. The field of view will be 192 x 192 mm with a 64 x 64 mm matrix resolution. With this phase encoding, the spatial resolution will be 3 mm, with an echo time (TE) of 25 ms, a repetition time (TR) of 2.5 s, and a multi-slice imaging factor of 2 being employed. With these parameters, 170 volumes will be captured. To un-distort images, the GE-EPI fMRI data will be mapped to a non-distorted set of GE images from the same participant. Next, the non-distorted GE images will be mapped to the T1-weighted MPRAGE image. Finally, the T1-weighted MPRAGE will be mapped to the Montreal Neurological Institute (MNI) standardized brain template. In doing this, the GE-EPI fMRI data will be mapped to the MNI template with maximum accuracy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The description is provided in the treatment arm description.
Time frame: Week 1, Week 16
fMRI will be administered to observe any changes in structure.
Time frame: Week 1, Week 8, Week 16, 6 Months
Y-BOCS will be administered to analyze changes in symptoms from treatment. Scale of 0-4 for each question with 0 being no symptom severity and 4 being high symptom severity
Time frame: Week 1, Week 8, Week 16, 6 months
OCI-R will be administered to analyze changes in symptoms from treatment. Scale of 0-4 with 0 being not at all and 4 being extreme severity.
Time frame: Week 1, Week 8, Week 16, 6 months
Q-LES-Q will be administered to analyze changes in quality of life from treatment. Scale of 0-5 for each question with 0 being not at all and 5 being frequently
Time frame: Week 1, Week 8, Week 16, 6 Months
SDS will be administered to analyze changes in levels of functioning. Scale of 0-10, 10 being the worst.
Callum Stephenson
Other
Using Electronically Delivered Cognitive Behavioural Therapy and Functional Magnetic Resonance Imaging to Understand the Pathophysiology of Obsessive-compulsive Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05552014
Anxiety Disorders, Mental Disorders
Hefei, Anhui, China
View Trial DetailsNCT04967560
Anxiety Disorders, Mental Disorders
Zhengzhou, Henan, China
View Trial DetailsNCT05503017
Anxiety Disorders, Generalized Anxiety Disorder
Tallahassee, Florida, United States
View Trial DetailsNCT04693351
Anxiety Disorders, Mental Disorders
Phoenix, Arizona, United States
View Trial Details